touchCONGRESS Advancing the treatment of MDS and AML: An update from ASH 2021
Watch this two-part activity exploring recent data on new and emerging treatments for patients with higher-risk MDS and newly diagnosed AML, filmed following the ASH 2021 Annual Meeting & Exposition.
Part 1: Watch leading haematology expert, Prof. Pierre Fenaux, review key data from ASH 2021 Watch Now
Part 2: Choose from three leading experts who discuss what these data may mean for global and regional practice Select An Interview
Introduction and venetoclax
Sabatolimab, pevonedistat and triplet combinations
Targeting TP53, IDH and FLT3 mutations
CPX-351 and summary
Overview
Watch Prof. Pierre Fenaux summarize and share his interpretation of the latest data from ASH 2021 on novel treatments for higher-risk MDS and newly diagnosed AML. During the presentation he considers:
- Venetoclax in patients with higher-risk MDS and newly diagnosed AML
- Sabatolimab, pevonedistat and triplet combinations in patients with higher-risk MDS and newly diagnosed AML
- Targeting TP53, IDH and FLT3 mutations in patients with higher-risk MDS and newly diagnosed AML
- CPX-351 in patients with higher-risk MDS
Prof. Pierre Fenaux is Head of the Hematology Department of Saint-Louis Hospital, Robert Debré Hospital and Avicenne Hospital (belonging to Assistance Publique-Hôpitaux de Paris Hospital network), and Professor of Hematology at the University of Paris, France. He is also part of the Inserm research unit n° 944 at Hôpital St Louis, Paris, with regards to his laboratory research. read more
Prof. Fenaux is involved in clinical and laboratory research in the field of MDS and AML, mainly AML in the elderly and patients with acute promyelocytic leukaemia (APL). He is a founding member and chairman of the French-speaking MDS group (Groupe Francophone des Myélodysplasies or GFM) and of the French APL group (GT-LAP).
Prof. Pierre Fenaux discloses: Honoraria and research grants from Abbvie, BMS, Janssen, Jazz and Novartis.
Prof. Pierre Fenaux considers the latest data on novel treatments for patients with higher-risk MDS and newly diagnosed AML from ASH 2021.
In this interview, Prof. Pierre Fenaux answers the following questions:
- What have we learned about targeting specific mutations in MDS, and how will this impact the treatment landscape in the future?
- Based on presentations at ASH 2021, what other emerging treatments for higher-risk MDS are likely to influence clinical practice?
- What have we learned about targeting specific mutations in patients with newly diagnosed AML not eligible for intensive chemotherapy, and how will this impact the treatment landscape in the future?
- Based on presentations at ASH 2021, what other emerging treatments for patients with newly diagnosed AML unfit for intensive chemotherapy are likely to influence clinical practice?
- What do presentations at ASH 2021 tell us about treatment personalization for patients with higher-risk MDS and newly diagnosed AML who are unfit for intensive chemotherapy?
Prof. Pierre Fenaux is Head of the Hematology Department of Saint-Louis Hospital, Robert Debré Hospital and Avicenne Hospital (belonging to Assistance Publique-Hôpitaux de Paris Hospital network), and Professor of Hematology at the University of Paris, France. He is also part of the Inserm research unit n° 944 at Hôpital St Louis, Paris, with regards to his laboratory research. read more
Prof. Fenaux is involved in clinical and laboratory research in the field of MDS and AML, mainly AML in the elderly and patients with acute promyelocytic leukaemia (APL). He is a founding member and chairman of the French-speaking MDS group (Groupe Francophone des Myélodysplasies or GFM) and of the French APL group (GT-LAP).
Prof. Pierre Fenaux discloses: Honoraria and research grants from Abbvie, BMS, Janssen, Jazz and Novartis.
Dr Esther Oliva considers the latest data on novel treatments in higher-risk MDS and newly diagnosed AML from ASH 2021.
In this interview, Dr Esther Oliva answers the following questions:
- What have we learned about targeting specific mutations in MDS, and how will this impact the treatment landscape in the future?
- Based on presentations at ASH 2021, what other emerging treatments for higher-risk MDS are likely to influence clinical practice?
- What have we learned about targeting specific mutations in patients with newly diagnosed AML not eligible for intensive chemotherapy, and how will this impact the treatment landscape in the future?
- Based on presentations at ASH 2021, what other emerging treatments for patients with newly diagnosed AML unfit for intensive chemotherapy are likely to influence clinical practice?
- What do presentations at ASH 2021 tell us about treatment personalization for patients with higher-risk MDS and newly diagnosed AML who are unfit for intensive chemotherapy?
Dr Esther Oliva is Associate Professor of Blood Diseases, Oncology and Rheumatology, and leads the MDS, aplastic anaemia and anaemia section of the Hematology Unit at the Grande Ospedale Metropolitano in Reggio Calabria, Italy. read more
Dr Oliva developed a unique instrument for the evaluation of quality of life (QoL) in patients with MDS (QOL-E), and the Haematological Malignancy Patient-Reported Outcome Measure (HM-PRO). Additionally, she has developed and coordinated clinical trials in pharmacology and QoL research.
Dr Oliva is a junior editor of the American Journal of Blood Research and associate editor of Frontiers in Oncology – Hematological Malignancies. She was the former chair and is now the co-chair of the European Hematology Association (EHA) Scientific Working Group ‘Quality of Life and Symptoms’. She is a founding member and vice president of the QOL-ONE research association. Dr Oliva is also an active member of the EHA, American Society of Hematology, International Society of Quality of Life, and Italian Society of Hematology.
Dr Esther Oliva discloses: Advisory board fees from Alexion, Amgen, Celgene/BMS, Janssen and Novartis. Consultancy fees from Alexion and Celgene/BMS. Speaker fees from Amgen, Celgene/BMS and Novartis. Royalties from Celgene/BMS.
Prof. Andrew Wei considers the latest data on novel treatments in higher-risk MDS and newly diagnosed AML from ASH 2021.
In this interview, Prof. Andrew Wei answers the following questions:
- What have we learned about targeting specific mutations in MDS, and how will this impact the treatment landscape in the future?
- Based on presentations at ASH 2021, what other emerging treatments for higher-risk MDS are likely to influence clinical practice?
- What have we learned about targeting specific mutations in patients with newly diagnosed AML not eligible for intensive chemotherapy, and how will this impact the treatment landscape in the future?
- Based on presentations at ASH 2021, what other emerging treatments for patients with newly diagnosed AML unfit for intensive chemotherapy are likely to influence clinical practice?
- What do presentations at ASH 2021 tell us about treatment personalization for patients with higher-risk MDS and newly diagnosed AML who are unfit for intensive chemotherapy?
Prof. Andrew Wei is an Adjunct Professor and Haematologist at the Alfred Hospital, and Metcalf Fellow at Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia. He leads the AML programme at the Alfred hospital as principal investigator, conducting clinical and translational research in AML. read more
Prof. Wei has authored over 130 publications in peer-reviewed journals and has been the AML working party chairperson for the Australasian Leukaemia and Lymphoma Group (ALLG) since 2009.
Prof. Andrew Wei discloses: Advisory board/speakers bureau fees from Abbvie/Genentech, Amgen, Astellas, AstraZeneca, Celgene/BMS, Gilead, Janssen, MacroGenics, Novartis, Pfizer, Servier and Syndax. Consultancy fees from Astellas, Gilead, Janssen, Servier and Syndax. Honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Gilead, Janssen, MacroGenics, Novartis, Pfizer, Servier and Syndax. Research grants from Abbvie, Amgen, Astellas, Astex, AstraZeneca, Celgene/BMS, Genentech, Novartis, Servier and Syndax.
Prof. Wei is also an employee of the Walter and Eliza Hall Institute (WEHI) and is eligible for financial benefits associated with payments which WEHI receives in relation to venetoclax.
Please Select A Video:
Learning Objectives & Overview
Overview
Stay up to date with the latest data on novel treatments for higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukaemia (AML) in this two-part activity. Filmed following ASH 2021.
Learning Objectives
After watching this activity, participants should be better able to:
- Recall the latest data for emerging therapeutic strategies for patients with HR-MDS
- Summarize data for emerging treatments for patients with AML who are unfit for intensive chemotherapy
- Discuss advances in treatment personalization and monitoring for patients with HR-MDS or AML
Register to touchONCOLOGY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
